|
|
Volumn 12, Issue 4, 2013, Pages 259-260
|
|
Antibody-drug conjugates
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY CONJUGATE;
BRENTUXIMAB VEDOTIN;
CAPECITABINE;
CD19 ANTIGEN MONOCLONAL ANTIBODY MAYTANSINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
GLEMBATUMUMAB VEDOTIN;
INOTUZUMAB OZOGAMICIN;
KADCYLA;
LAPATINIB;
LORVOTUZUMAB MERTANSINE;
MGN 901;
PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODY VEDOTIN;
RG 7593;
RG 7596;
RITUXIMAB;
SAR 3419;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
UNCLASSIFIED DRUG;
ACUTE LYMPHOBLASTIC LEUKEMIA;
BREAST METASTASIS;
CHRONIC LYMPHATIC LEUKEMIA;
COOPERATION;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TOLERABILITY;
FINANCIAL MANAGEMENT;
FOLLICULAR LYMPHOMA;
FOOD AND DRUG ADMINISTRATION;
HODGKIN DISEASE;
HUMAN;
LARGE CELL LYMPHOMA;
LUNG SMALL CELL CANCER;
MELANOMA;
MULTIPLE MYELOMA;
NONHODGKIN LYMPHOMA;
NOTE;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROSTATE CANCER;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
IMMUNOCONJUGATES;
MAYTANSINE;
MOLECULAR TARGETED THERAPY;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 84875748562
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3980 Document Type: Note |
|
Times cited : (181)
|
|
References (3)
|
